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Abstract
Background: With the remarkable improvements in ultrasound equipment, transabdominal ultrasound after oral
administration of an echoic cellulose-based gastric ultrasound contrast agent (TUS-OCCA) has recently been suggested
to be effective in initial screening of gastric cancer. The aim of this study was to evaluate the diagnostic value of
TUS-OCCA for gastric cancer.
Methods: Consecutive patients with gastric cancers who underwent resection in our hospital were enrolled.
Before the lesion was resected, TUS-OCCA examination was performed by a skilled examiner who was blinded to
the site, size, and endoscopy diagnosis of the lesion. TUS-OCCA findings were compared with those of
endoscopy and pathological diagnoses as the gold standard.
Results: There were a total of 288 consecutive patients enrolled in the study, including 228 with advanced gastric
cancers (T2–T4 stage), 50 with early gastric cancer (26 with stage T1b and 24 with stage T1a), and 10 with high-grade
intraepithelial neoplasia. TUS-OCCA had a detection rate of 100 % (228/228) for advanced gastric cancers, 77 % (20/26)
for stage T1b, 67 % (16/24) for stage T1a, and 60 % (6/10) for high-grade intraepithelial neoplasia. The majority of patients
with undetectable neoplasms using TUS-OCCA were obese (body mass index, 28.7–31.8 kg/m2). The overall accuracy of
TUS-OCCA in determining the T stage of gastric cancer was 77.3 % (62.5 % for T1a, 70 % for T1b, 71.1 % for T2, 85.2 % for
T3, and 73.3 % for T4).
Conclusions: These findings indicate that TUS-OCCA achieved a high detection rate for gastric cancers and was useful in
assessing the degree of gastric cancer invasion.
Keywords: Cellulose-based ultrasound contrast agent, Detection rate, Gastric cancer, Initial screening, Transabdominal
ultrasound
Background
Gastric cancer is the fourth most common cancer and
the second leading cause of cancer-related death world-
wide [1–3]. The use of gastroscopy for opportunistic
screening of gastric cancers is widely accepted; however,
the employment of this procedure for mass screening of
gastric cancers remains questionable, even in developed
countries such as Japan [1–3]. Therefore, the barium
swallow test continues to be the most common mass
screening tool for gastric cancers in Japan and Korea
[1–3]. However, a simple, economic, efficient, and non-
invasive approach for mass screening of gastric lesions
would be welcome.
Transabdominal ultrasound is increasingly used for the
detection and evaluation of gastrointestinal lesions [4–11].
However, the diagnostic value of transabdominal ultra-
sound after oral administration of an echoic cellulose-
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based gastric ultrasound contrast agent (TUS-OCCA) for
gastric cancer remains unclear. The purpose of this study




The study protocol was approved by the Ethics Commit-
tee of Sheng Jing Hospital, China Medical University
(Liaoning, China), and informed consent was obtained
from all patients prior to enrollment.
Patients
From May 1, 2012 to June 1, 2015, consecutive patients
who underwent resection in our hospital for gastric cancer
and high-grade intraepithelial neoplasia were prospect-
ively enrolled in this study. All of the enrolled subjects
underwent an endoscopic examination and biopsy in our
hospital or an affiliated facility approximately 1 week be-
fore surgery. For subgroup analysis, the enrolled patients
were classified into two groups according to body habitus:
Group S (suitable body habitus) and Group U (unsuitable
body habitus). Group S included patients considered suit-
able for TUS-OCCA (visualization of the cardia and pyl-
orus, as shown in Fig. 1a and b), while Group U included
patients deemed less suitable for TUS-OCCA (inability to
visualize the cardia or pylorus, as shown in Fig. 1c and d).
The body habitus characteristics of the enrolled patients
were evaluated using conventional transabdominal ultra-
sound before oral administration of contrast agent. The
patients were subsequently classified into Groups S and U
before TUS-OCCA examination was performed.
TUS-OCCA examination
All TUS-OCCA examinations were performed before le-
sion resection by an investigator with 5 years of experience
(ZJL) who was blinded to the site, size, and endoscopic
diagnosis of the lesion; however, he was aware of the pres-
ence of gastric lesions scheduled to be resected surgically
or endoscopically. Sonographic examinations were per-
formed using the Toshiba Aplio 400 (Toshiba Medical Sys-
tems Corporation, Tokyo, Japan), Hitachi 8500 (Hitachi,
Ltd., Tokyo, Japan), or IU22 (Philips Healthcare, Bothell,
WA, USA) systems with a 2–5 MHz convex array probe.
Fig. 1 Definition of Groups S and U. a Visualization of the cardia (arrows) between the liver and aorta is acceptable. b Visualization of the pylorus
(arrows) between the liver and pancreas is also acceptable. c The cardia between the liver and aorta is not acceptably visualized. d The pylorus
between the liver and pancreasis is not acceptably visualized. Visualization of the cardia and pylorus is acceptable in Group S, but not in Group U.
An, antrum; P-head, pancreatic head
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Cellulose-based oral contrast agent
The ultrasound contrast agent used was the World instant
gastrointestinal ultrasound agent (Huzhou East Medical
Devices, Huzhou, Zhejiang, China). It was reconstituted in
500 mL of boiling water, which formed a homogeneous
thin paste. This was cooled to a suitable temperature and
then administered orally to improve stomach distension.
The uniform thin paste formed by this cellulose-based con-
trast agent reportedly had a pleasant taste (slightly sweet)
and was well tolerated by most patients. TUS-OCCA
examination was performed at approximately 1 min after
the contrast agent was swallowed by the patient. The
acoustic velocity and specific acoustic impedance of the
contrast agent were similar to those of liver tissue. The
stomach, once filled with the cellulose-based ultrasound
contrast agent, appeared as a homogeneous mid- to high-
level echogenicity. No antispasmodics were used.
Stomach scanning procedure
The whole stomach was scanned in five views as follows
(Fig. 2): (1) mainly the gastric cardia (Fig. 2a and b) and
then the gastric fundus (Fig. 2c), which was performed
by moving the probe from the xiphoid process to the left
costal arch, with the subject in the supine position; (2)
mainly the gastric fundus (Fig. 2d), which was performed
by placing the probe at the location of the left intercostal
space; (3) the gastric fundus, body, and antrum in a
transverse section (Fig. 2e–h), which was performed by
moving the probe from the left costal arch to the right
costal arch, with the subject lying in the right decubitus
position; (4) the gastric fundus, body, and antrum in a
coronal section (Fig. 2i–k), which was performed by ro-
tating the probe along the left costal arch, while using
the caudal end of the probe as an axis (simultaneously
tilting the probe at ~45°) with the subject lying in the
right decubitus position; and (5) the gastric antrum
(Fig. 2l), which was performed by placing the probe ver-
tically to the right costal arch, with the subject lying in
the supine position. Views 3 (Fig. 2e–h) and 4 (Fig. 2i–k)
were key to obtaining serial transverse and coronal sec-
tions, respectively, of the whole stomach including the
gastric fundus, body, angle, and antrum.
Sonographic criteria
The sonographic criteria for the diagnosis of stomach neo-
plasms were based on recommendations in the literature
Fig. 2 Normal sections of the contrast-filled whole stomach obtained in five views: (1) sagittal section of the a lower esophagus (white arrow), b
gastric cardia (white arrow), and c oblique section of the gastric fundus (cardia; white arrow); (2) d transverse section of the gastric fundus; (3) serial
transverse sections of e gastric fundus, f body, g angle, and h antrum (black arrow; transverse section of the gastric angle); (4) serial coronal sections of
i gastric fundus, j body, k angle and antrum (black arrow; coronal section of the gastric angle); and (5) l longitudinal section of the gastric antrum.
P, pancreas
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[12, 13] and our previous experience. Gastric high-grade
intraepithelial neoplasia and intramucosal (stage T1a)
early gastric cancer presented on ultrasonograph scans as
hypoechoic thickening of the mucosal layer, with the
hyperechoic submucosal layer intact. Early gastric cancer
involving the submucosal layer (stage T1b) presented as
hypoechoic thickening of the mucosal and submucosal
layers, with the hypoechoic muscularis propria layer in-
tact. Advanced gastric cancers (stage T2–T4) presented as
hypoechoic thickening of the gastric wall with disruption
to the muscularis propria layer. Features, such as tumor
size, site, and echo pattern, were recorded during each
TUS-OCCA examination and the findings were compared
with those of endoscopic and pathological diagnoses.
All statistical analyses were performed using the Fish-
er’s exact test with SPSS statistical software (version
21.0: IBM-SPSS, Inc., Chicago, IL, USA). A probability
(p) value < 0.05 was considered statistically significant.
Results
A total of 288 patients (178 men and 110 women; mean
age, 54.6 years; age range, 32–83 years) who underwent
treatment for gastric cancer and high-grade intraepithelial
neoplasia were enrolled. Patients included 228 with ad-
vanced gastric cancers (stage T2–T4 stage), 50 with early
gastric cancers (26 with stage T1b and 24 with stage T1a),
and 10 with high-grade intraepithelial neoplasia. Accord-
ing to the habitus characteristics evaluated using transab-
dominal ultrasound, 184 (64 %) patients were classified
into Group S and 104 (36 %) into Group U.
As shown in Table 1, TUS-OCCA achieved a detection
rate of 100 % (228/228) for advanced gastric cancers, 77 %
(20/26) for stage T1b early gastric cancer, 67 % (16/24) for
stage T1a early gastric cancer, and 60 % (6/10) for high-
grade intraepithelial neoplasia. Subgroup analysis of the
detection rates for TUS-OCCA in the patients within
Group S (146 patients with advanced gastric cancer, 32
patients with early gastric cancer, and 6 with high-grade
intraepithelial neoplasia) was 100 % (184/184). The detec-
tion rates for TUS-OCCA in the patients in Group U were
83 % (86/104) (including 100 % (82/82) for advanced gas-
tric cancers, 18 % (4/22) for early gastric cancer and high-
grade intraepithelial neoplasia). The 14 patients with early
gastric cancer and four with high-grade intraepithelial
neoplasia who were undetected using TUS-OCCA exam-
ination were in Group U. The difference in the detection
rates between Groups S and U (100 % vs. 83 %) was statis-
tically significant (p < 0.05, Fisher’s exact test).
Subgroup analysis data regarding the detection rates
using TUS-OCCA evaluated according to the location of
the lesions are detailed in Table 2. For lesions located in
the antrum, the detection rate was 95 % (87/92); for le-
sions located in the angle, the detection rate was 96 %
(70/73); for lesions located in the body, the detection
rate was 97 % (38/39); for lesions located in the fundus,
the detection rate was 63 % (5/8); and for lesions located
in the cardia, the detection rate was 92 % (70/76).
As detailed in Table 3, the overall accuracy of TUS-
OCCA in determining the T stage of gastric cancer was
77.3 % (62.5 % for T1a, 70 % for T1b, 71.1 % for T2,
85.2 % for T3, and 73.3 % for T4). Figures 3 and 4 show
examples of early and advanced gastric cancers, respect-
ively on TUS-OCCA images.
Discussion
Because gastric cancer is the second leading cause of
cancer-related death worldwide, it is important in terms of
the further development of anticancer strategies [14–16].
The 5-year survival rate for gastric cancers at stages IA,
IB, II, IIIA, IIIB, and IV are reportedly 92.2, 85.3, 72.1,
52.8, 31.0, and 14.9 %, respectively [17]. Hence, earlier de-
tection of gastric cancers will enable better prognosis.
Various imaging modalities are used to detect gastric le-
sions, including endoscopy, barium studies, computed
tomography, magnetic resonance imaging, and ultrasound
[18–21]. Nevertheless, to date, no suitable mass screening
tool for gastric cancer has been recommended by the
World Health Organization; hence, there is a need for a
method that is relatively safe, simple, inexpensive, and reli-
able [22]. Gastroscopy appears to be the most accurate
method for the detection of gastric lesions; however, pa-
tient discomfort, risk of cross-infection, the high cost of
screening, and the lack of experienced endoscopists ham-
per its application. Therefore, barium swallow continues
Table 1 Detection rates for gastric cancer and high-grade intraepithelial neoplasia using TUS-OCCA
Gastric cancer and premalignant
lesions
Detection rates Total
Group S Group U
High grade intraepithelial neoplasia 6/6 0/4 6/10 (60 %)
Stage T1a early gastric cancer 14/14 2/10 16/24 (67 %)
Stage T1b early gastric cancer 18/18 2/8 20/26 (77 %)
Advanced gastric cancer (stage T2 ~ T4) 146/146 82/82 228/228 (100 %)
Total 184/184 (100 %) 86/104 (83 %) 270/288 (94 %)
TUS-OCCA, transabdominal ultrasound after oral administration of an echoic cellulose-based contrast agent. The difference in the detection rates between Groups
S and U (100 % vs. 83 %) was significant (p < 0.05, Fisher’s exact test)
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to be the main choice for mass screening of gastric can-
cer in Japan and Korea [1–3]. In Japan, approximately
4,000,000 individuals undergo barium swallow testing
annually, and about 10 % of those with abnormal re-
sults are further screened using endoscopy [2]. More-
over, an additional 1,000,000 individuals in Korea
undergo barium studies annually [3]. However, the bar-
ium swallow test is an observational approach and its
ability is somewhat limited. In addition, barium studies
are quite invasive in terms of complications, especially
constipation and mis-swallowing of the barium into the
trachea [23]. In consideration of these complications, a
simple, economic, efficient, and noninvasive approach
for mass screening of gastric cancer would be welcome.
With the remarkable improvements in ultrasound
equipment, TUS-OCCA has recently been suggested by
some authors to be effective in initial gastric cancer
screening for selected individuals [4–7]. The reported
benefits of the mid-high echoic cellulose-based gastro-
intestinal contrast agent include the following [4–6, 24]:
(1) fewer gas artifacts than water because of the superior
bulk and surface tension properties, which optimize gas
displacement and interfere with mural gas adherence
(Fig. 5a and b); (2) the uniform mid to high level of
echogenicity provided by this cellulose-based contrast
agent can improve the ultrasonic visualization of hypoe-
choic gastric lesions (Fig. 6a and b); and (3) small gastric
lesions can be detected much easier because gastric muco-
sal folds are more effectively flattened by this thin paste
cellulose-based contrast agent.
Some previous comparative studies have reported that
TUS-OCCA was remarkably accurate in the detection of
various gastric lesions, with sensitivities of 77.8–100 %
and specificities of 94–100 % [4–6]. Li et al. [7] clearly
demonstrated the morphological features of 350 gastric
lesions using transabdominal ultrasonography, including
53 located in the cardia, 70 in the fundus, 90 in the
body, 99 in the antrum, and 38 in the pylorus. Shi et al.
[8] reported that transabdominal ultrasound clearly
demonstrated the anatomy of the stomach and the mor-
phological features of various gastric lesions in all 46 pa-
tients evaluated, including 5 with chronic gastritis, 9
with gastric ulcers, 3 with gastric polyps, 5 with gastric
stromal tumors, 24 with gastric cancers, and 1 with
postoperative recurrent gastric cancer.
The ability of TUS-OCCA to detect gastric lesions is in-
fluenced by the body habitus, as well as the location, size,
and echogenicity of the gastric lesion. Body habitus is an
important influential factor. As detailed in Table 1, the de-
tection rate for stomach neoplasms using TUS-OCCA in
Group S was greater than that in Group U (100 % vs.
83 %). Therefore, TUS-OCCA is strongly suggested for se-
lected individuals, especially those considered non-obese
with a suitable body habitus (visualization of the cardia
and pylorus) [4–6]. As is known, conventional transab-
dominal ultrasound has been widely used for population-
based mass screening of abdominal cancers (such as liver,
gallbladder, pancreas, kidney, bladder, and others). An indi-
vidual’s body habitus can be assessed during conventional
transabdominal ultrasound examination [6]. For indi-
viduals with a suitable body habitus, TUS-OCCA exam-
ination could then be strongly suggested for gastric
cancer screening [6].
Location is also an important influential factor. The le-
sions located in the gastric antrum and body were much
easier to detect than those in the fundus (Table 2); the
detection rate achieved using TUS-OCCA for lesions lo-
cated in the fundus was relatively low (only 63 %). Be-
cause the fundus is situated relatively deeply in the body
(usually at depths >15 cm) during transabdominal ultra-
sound scanning from the left costal arch and left inter-
costal space, the ultrasound imaging of far field of the
fundus is blurred [4–7]. In addition, scanning of near
field of the fundus would be hampered by the costal
bone when locating the probe from the left intercostal
space. In other words, unlike the antrum and the body,
scanning of the whole fundus is not very satisfactory
[4–7]. Fortunately, gastric cancer located in the fundus
is rare. As has been established, the majority of gastric
malignant neoplasms and precancerous lesions infil-
trate the gastric lesser curvature (including pylorus,
Table 2 Detection rates for gastric cancer and high-grade
intraepithelial neoplasia using TUS-OCCA (data analyzed according
to location)
Location of lesions Patients (n) Detection rates of TUS-OCCA
Antrum 92 87/92 (95 %)
Angle 73 70/73 (96 %)
Body 39 38/39 (97 %)
Fundus 8 5/8 (63 %)
Cardia 76 70/76 (92 %)
Total 288 270/288 (94 %)
TUS-OCCA, transabdominal ultrasound after oral administration of an echoic
cellulose-based gastric ultrasound contrast agent
Table 3 Results of T staging using TUS-OCCA as compared with
the pathological findings (by case)
Pathology TUS-OCCA Accuracy
T1a T1b T2 T3 T4
T1a 10 6 0 0 0 62.5 % (10/16)
T1b 2 14 4 0 0 70.0 % (14/20)
T2 0 4 54 18 0 71.1 % (54/76)
T3 0 0 12 104 6 85.2 % (104/122)
T4 0 0 0 8 22 73.3 % (22/30)
TUS-OCCA, transabdominal ultrasound after oral administration of an echoic
cellulose-based ultrasound contrast agent. The overall accuracy of TUS-OCCA
for T-staging was 77.3 % (204/264)
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angle, and cardia) and antrum, rather than the gastric
fundus [25, 26].
The echogenicity of lesions is another important influ-
ential factor. In our experience, the detection rates of
TUS-OCCA for gastric polyps, which usually present with
a mid to high echo, are low; the detection rates of TUS-
OCCA for gastric cancer, which usually presents as hypoe-
choic thickening of the gastric wall, are high.
The most important reason why TUS-OCCA is cur-
rently performed and continues to be investigated is that
Fig. 3 Early gastric cancer. a Examination involving transabdominal ultrasound scans after oral administration of an echoic cellulose-based gastric
ultrasound contrast agent showing hypoechoic mucosal thickening of the gastric wall (black arrows). b Endoscopic ultrasound showing hypoechoic
mucosal thickening of the gastric wall (white arrows). c and d Endoscopic resection of a lesion confirmed as early gastric cancer
Fig. 4 Advanced gastric cancer. a and b Examination involving transabdominal ultrasound scans after oral administration of an echoic cellulose-based
gastric ultrasound contrast agent showing hypoechoic thickening of the gastric wall with superficial ulceration (a, longitudinal section; b, cross section).
c Gastroscopic examination showing the lesion. Arrow, pointing at the lesion
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the pathological regression of various gastric lesions has
been better elucidated over the past 5 years. In defense
of this position, the following factors should be consid-
ered: (1) the majority of gastric polyps are benign and
are believed to possess no malignant potential [27–30];
(2) gastric precancerous lesions are usually composed of
gastric mucosa with intestinal metaplasia or dysplasia
presenting as hypoechoic mucosal thickening [31, 32]. Al-
though the detection rate using TUS-OCCA for gastric
polyps (which usually require no further treatment) is low,
the detection rate for hypoechoic thickening of the gastric
wall (which requires further treatment) is high.
One limitation of our study in common with others was
that the gastric lesions of the enrolled patients were previ-
ously detected in gastroscopic examinations; this may have
influenced the higher accuracy rates for the detection of
the lesions, even though the examiner was blinded to the
site, size, and endoscopic diagnosis of the lesions. Another
limitation of the study is that it lacked negative controls,
which also limited its accuracy.
In our experience, the sensitivity and specificity of TUS-
OCCA for gastric dysplasia and cancer were 90.8 and
96 %, respectively [6]. The majority of patients whose le-
sions were undetected using TUS-OCCA were obese, and
were classified into Group U [6]. In our experience, about
70 % of the population would be classified into Group S
and about 30 % would be classified into Group U. Al-
though TUS-OCCA examination is not suggested by
ultrasonic physicians for patients classified into Group U,
many still want to simultaneously undergo TUS-OCCA
for mass screening of gastric cancer when they undergo
conventional transabdominal ultrasound examination for
mass screening of abdominal cancer. Certainly, written in-
formed consent should be obtained from patients after
they have been advised regarding the limits and disadvan-
tages of TUS-OCCA. We believe that with promotion of
Fig. 5 Cellulose-based contrast agent may provide fewer gas artifacts than water. a Mural gas and gastric mucus adherence to the gastric wall
was increased when the stomach was filled with water, which may influence observations of the gastric wall. b Mural gas and gastric mucus
adherence to the gastric wall were reduced when the stomach was filled with cellulose-based contrast agent, as a result of its greater bulk and
surface tension properties, which optimize gas displacement and interfere with mural gas adherence
Fig. 6 As compared with water, the uniformity of the mid to high echoic contrast agent may improve ultrasound visualization of hypoechoic gastric
tumors. a Because the echo intensity of the tumor was similar to that of the gastric fluid floating above the cellulose-based contrast agent, visualization
of the hypoechoic tumor was blurred and unclear. b The uniformity of the mid to high echoic contrast agent could improve ultrasound visualization
of the hypoechoic gastric tumors. Arrow, pointing at the hypoechoic tumor
Liu et al. BMC Cancer  (2015) 15:932 Page 7 of 8
the TUS-OCCA technique and training in its use, it could
be used as an alternative mass screening tool for gastric
cancers, especially in the Asian population (China, Japan,
and Korea) where the incidence of the disease is high and
the body habitus of the population is more suitable.
Conclusions
TUS-OCCA achieved a high detection rate for gastric
cancers, especially in patients with a suitable body hab-
itus whose cardia and pylorus could both be visualized
using transabdominal ultrasound. TUS-OCCA could be
used to assess the depth of gastric cancer invasion. Many
more successive studies will be needed to fully evaluate
the utility of TUS-OCCA.
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